Third, formal budget-impact and cost-effectiveness models should quantify the medium-term fiscal implications of expanding GLP-1-based and SGLT-2 indications, including obesity and MASLD, under alternative reimbursement and pricing scenarios. This evidence concerns the gene SLC5A2 and obesity disorder.